NCT05312151已完成2 期
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 3
- 主要终点
- Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
研究概览
简要总结
The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder
详细描述
The Safety and Tolerability of COMP360 administered under supportive conditions in participants with Post-traumatic Stress Disorder
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Meet DSM-5 criteria for current PTSD resulting from a trauma experienced during adulthood measured via the PCL-5 in combination with the LEC-5 at screening
- •Meet DSM-5 criteria for current PTSD resulting from a trauma experienced during adulthood as assessed by the CAPS, with a minimum score of 25 at baseline
- •Able to identify a next of kin who is willing and able to be reached by the investigators in case of emergency
- •Have successfully discontinued all prohibited medications at least two weeks prior to baseline visit. For fluoxetine (Prozac), immediate cessation at screening period visit 1a followed by at least four weeks of run-in will be required prior to baseline
排除标准
- •Current or past history of schizophrenia, schizoaffective disorder or any other form of psychotic disorder, obsessive compulsive disorder, personality disorders, bipolar disorder, or any other significant disorder as assessed by clinician judgement and a structured clinical interview (MINI 7.0.2)
- •Diagnosis of complex PTSD according to clinician judgement
- •Borderline Personality Disorder as demonstrated by both the McLean Screening Instrument for Borderline Personality Disorder (MSI- BPD) score ≥ 7 and clinical confirmation of diagnosis by the study clinician and Medical Monitor
- •Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within the past year, during screening or at baseline, or; (2) suicidal behaviours within the past year, or; (3) history of serious suicide attempt that required a rescuing medical intervention, or; (4) clinical assessment of significant suicidal risk during participant interview
- •Current (within the last year) alcohol or substance use disorder as informed by DSM-5 assessed via the MINI 7.0.2 at screening
- •Other personal circumstances and behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin
- •Exposure to 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide (LSD), or peyote in the past year
- •Primary diagnosis of major depressive disorder within 6 months of study entry
- •Exposure to a traumatic experience in the past 3 months
- •Significant childhood physical or sexual abuse based on clinician judgment with the use of CTQ
- •Enrolment in a psychological therapy programme that will not remain stable for the duration of the study. Psychological therapies cannot have been initiated within 21 days of baseline
研究组 & 干预措施
COMP360 Psilocybin
Experimental
25 mg COMP360 Psilocybin
干预措施: Psilocybin (Drug)
结局指标
主要结局
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
时间窗: Up to 12 weeks
A TEAE is defined as an adverse event (AE) that has an onset on or after the dose of study drug, or any pre-existing AE condition that has worsened on or after the dose of study drug.
次要结局
- Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score From Baseline(Week 12)
- Proportion of Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Responders(Week 12)
- Proportion of Clinician-Administered PTSD Scale From DSM-5 (CAPS-5) Remitters.(Week 12)
- Change in Sheehan Disability Scale (SDS) Total Score From Baseline(Week 12)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaJPRN-jRCT2080223264AstraZeneca40
进行中（未招募）
1 期
A clinical trial in patients with liver cancer that cannot be removed by surgery, investigating the safety, tolerability, and clinical activity of investigational drugs MEDI4736 and tremelimumab. The study will look at the effect of these two drugs either as a single agents (monotherapy) or as combination therapy (when given together to patients).MedDRA version: 18.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864Hepatocellular CarcinomaEUCTR2015-001663-39-ESMedImmune120
进行中（未招募）
1 期
A clinical trial in patients with advanced liver cancer. The trial will investigate the safety, tolerability and clinical activitiy of durvalumab or tremelimumab as monoterapy, durvalumab combined with tremelimumab, or durvalumab combined with bevacizumabMedDRA version: 21.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864Hepatocellular CarcinomaEUCTR2015-001663-39-ITMEDIMMUNE, LLC456
已完成
2 期
Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI TransmissionChlamydia TrachomatisNeisseria GonorrhoeaeTrichomonas VaginitisHIV InfectionsSyphilisNCT00213018Population Council400
已完成
3 期
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseCOPDNCT02536508Pearl Therapeutics, Inc.627